Challenges and Opportunities for the Prevention and Treatment of Cardiovascular Disease Among Young Adults: Report From a National Heart, Lung, and Blood Institute Working Group
- PMID: 32993438
- PMCID: PMC7792379
- DOI: 10.1161/JAHA.120.016115
Challenges and Opportunities for the Prevention and Treatment of Cardiovascular Disease Among Young Adults: Report From a National Heart, Lung, and Blood Institute Working Group
Abstract
Improvements in cardiovascular disease (CVD) rates among young adults in the past 2 decades have been offset by increasing racial/ethnic and gender disparities, persistence of unhealthy lifestyle habits, overweight and obesity, and other CVD risk factors. To enhance the promotion of cardiovascular health among young adults 18 to 39 years old, the medical and broader public health community must understand the biological, interpersonal, and behavioral features of this life stage. Therefore, the National Heart, Lung, and Blood Institute, with support from the Office of Behavioral and Social Science Research, convened a 2-day workshop in Bethesda, Maryland, in September 2017 to identify research challenges and opportunities related to the cardiovascular health of young adults. The current generation of young adults live in an environment undergoing substantial economic, social, and technological transformations, differentiating them from prior research cohorts of young adults. Although the accumulation of clinical and behavioral risk factors for CVD begins early in life, and research suggests early risk is an important determinant of future events, few trials have studied prevention and treatment of CVD in participants <40 years old. Building an evidence base for CVD prevention in this population will require the engagement of young adults, who are often disconnected from the healthcare system and may not prioritize long-term health. These changes demand a repositioning of existing evidence-based treatments to accommodate new sociotechnical contexts. In this article, the authors review the recent literature and current research opportunities to advance the cardiovascular health of today's young adults.
Keywords: cardiovascular disease prevention; cardiovascular disease risk factors; primary prevention; young adults.
Conflict of interest statement
Dr Bacha received grants through her institution from Takeda and Astrazeneca with no relationship to the current work. Dr Gidding was a paid medical director of the FH Foundation. Dr Grandner is a consultant for Fitbit, Curaegis, Natrol, Thrive Global, Casper Sleep, Smartypants, Pharmavite, and Merck. Dr Robinson is a consultant for Amgen, Medicines Company, Merck, Novartis, Novo‐Nordisk, Pfizer, Regeneron, and Sanofi. Dr Spring is a scientific advisor to Actigraph and Apple. Dr Tate is on the Scientific Advisory Board for Weight Watchers. The remaining authors have nothing to disclose.
Figures
References
-
- O'Flaherty M, Buchan I, Capewell S. Contributions of treatment and lifestyle to declining CVD mortality: why have CVD mortality rates declined so much since the 1960s? Heart. 2013;99:159–162. - PubMed
-
- Ford ES, Capewell S. Coronary heart disease mortality among young adults in the U.S. from 1980 through 2002. J Am Coll Cardiol. 2007;50:2128–2132. - PubMed
-
- Pearson‐Stuttard J, Guzman‐Castillo M, Penalvo JL, Rehm CD, Afshin A, Danaei G, Kypridemos C, Gaziano T, Mozaffarian D, Capewell S, et al. Modeling future cardiovascular disease mortality in the United States: national trends and racial and ethnic disparities. Circulation. 2016;133:967–978. - PMC - PubMed
Publication types
MeSH terms
Grants and funding
- HHSN268201800003I/HL/NHLBI NIH HHS/United States
- R01 DK095078/DK/NIDDK NIH HHS/United States
- R01 HL107475/HL/NHLBI NIH HHS/United States
- R01 HL128666/HL/NHLBI NIH HHS/United States
- R01 MD011600/MD/NIMHD NIH HHS/United States
- R01 HL133860/HL/NHLBI NIH HHS/United States
- P2C HD050924/HD/NICHD NIH HHS/United States
- R01 HL130471/HL/NHLBI NIH HHS/United States
- R01 DK103668/DK/NIDDK NIH HHS/United States
- R01 HL127341/HL/NHLBI NIH HHS/United States
- R01 DK097364/DK/NIDDK NIH HHS/United States
- K23 HL122361/HL/NHLBI NIH HHS/United States
- R01 HL122144/HL/NHLBI NIH HHS/United States
- R21 HL145419/HL/NHLBI NIH HHS/United States
- P01 HD031921/HD/NICHD NIH HHS/United States
- R01 HL121230/HL/NHLBI NIH HHS/United States
- R01 HL132148/HL/NHLBI NIH HHS/United States
- R01 HL136942/HL/NHLBI NIH HHS/United States
- R01 DK108678/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Miscellaneous
